Literature DB >> 33421885

The value of intravoxel incoherent motion and diffusion kurtosis imaging in the assessment of tumor regression grade and T stages after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer.

Lanqing Yang1, Chunchao Xia1, Jin Zhao1, Xiaoyue Zhou2, Bing Wu3.   

Abstract

PURPOSE: To evaluate the role of IVIM and diffusion kurtosis imaging (DKI) in identifying pathologic complete response (pCR) and T stages after neoadjuvant chemoradiotherapy (nCRT) in locally advanced rectal cancer (LARC).
METHOD: Forty-two patients with biopsy-proven rectal adenocarcinoma, who underwent both pre-and post-CRT MRI with IVIM and DKI sequences on a 3 T scanner, were enrolled prospectively. According to the pathologic ypTNM stages and tumor regression grade (TRG), patients were grouped into pCR (TRG0) and non-pCR (TRG1-3) groups and low T stage (ypT0-2) and high T stage (ypT3-4) groups. IVIM parameters (the slow diffusion coefficient [D], fast diffusion coefficient [D*], perfusion fraction [f]), DKI parameters (mean diffusivity [MD] and mean kurtosis [MK]), and mono-exponential ADC were calculated and analyzed between groups.
RESULTS: The pCR group had significantly higher post-CRT ADC, D*, f, and MD values than non-pCR group, and higher percent changes in the ADC, f, and MD values (all P < 0.05). The post-CRT MD values yielded the highest AUC (0.788) with higher sensitivity than post-ADC values (82.9 % vs. 77.1 %, respectively). Post-CRT ADC and MD values and the percent changes in the ADC and MD values were also negatively correlated with TRG (all P < 0.05). Besides, negative correlations were found among the pre-CRT MD, post-CRT ADC, D, f, and MD values and the ypT stages (all P < 0.05).
CONCLUSIONS: Both IVIM and DKI parameters could provide more information when evaluating pCR and T stages after nCRT. In particular, the diagnostic performance of the MD values was more valuable than ADC values in being able to determine pCR.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diffusion magnetic resonance imaging; Neoadjuvant therapy; Rectal neoplasms

Mesh:

Year:  2020        PMID: 33421885     DOI: 10.1016/j.ejrad.2020.109504

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  5 in total

1.  Combining Clinicopathology, IVIM-DWI and Texture Parameters for a Nomogram to Predict Treatment Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients.

Authors:  Rixin Su; Shusheng Wu; Hao Shen; Yaolin Chen; Jingya Zhu; Yu Zhang; Haodong Jia; Mengge Li; Wenju Chen; Yifu He; Fei Gao
Journal:  Front Oncol       Date:  2022-05-27       Impact factor: 5.738

2.  Noninvasive assessment of clinical and pathological characteristics of patients with IgA nephropathy by diffusion kurtosis imaging.

Authors:  Ping Liang; Shichao Li; Guanjie Yuan; Kangwen He; Anqin Li; Daoyu Hu; Zhen Li; Chuou Xu
Journal:  Insights Imaging       Date:  2022-01-29

3.  Quantitative analysis of diffusion weighted imaging in rectal cancer during radiotherapy using a magnetic resonance imaging integrated linear accelerator.

Authors:  Manasi Ingle; Matthew Blackledge; Ingrid White; Andreas Wetscherek; Susan Lalondrelle; Shaista Hafeez; Shreerang Bhide
Journal:  Phys Imaging Radiat Oncol       Date:  2022-06-10

4.  Comparison of compressed sensing-sensitivity encoding (CS-SENSE) accelerated 3D T2W TSE sequence versus conventional 3D and 2D T2W TSE sequences in rectal cancer: a prospective study.

Authors:  Xiaoling Gong; Daguang Wen; Hong Wei; Yu Shen; Yujiao Deng; Ya Wang; Mingtian Wei; Xiaoxiao Zhang; Xiaoyong Zhang; Ziqiang Wang; Bing Wu
Journal:  Abdom Radiol (NY)       Date:  2022-08-23

5.  Optimized tools and timing of response reassessment after neoadjuvant chemoradiation in rectal cancer.

Authors:  Junbing Chen; Zhouqiao Wu; Xiaoyan Zhang; Zining Liu; Yiding Wang; Fei Shan; Yinkui Wang; Shaojun Xia; Yan Zhang; Yingshi Sun; Jiafu Ji; Ziyu Li
Journal:  Int J Colorectal Dis       Date:  2022-10-15       Impact factor: 2.796

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.